JP2004091491A - アレルギーを処置する際のいくつかのＬａｃｔｏｂａｃｉｌｌｕｓ株の新規使用 - Google Patents
アレルギーを処置する際のいくつかのＬａｃｔｏｂａｃｉｌｌｕｓ株の新規使用 Download PDFInfo
- Publication number
- JP2004091491A JP2004091491A JP2003310760A JP2003310760A JP2004091491A JP 2004091491 A JP2004091491 A JP 2004091491A JP 2003310760 A JP2003310760 A JP 2003310760A JP 2003310760 A JP2003310760 A JP 2003310760A JP 2004091491 A JP2004091491 A JP 2004091491A
- Authority
- JP
- Japan
- Prior art keywords
- ccrc
- lactobacillus
- lactic acid
- strain
- bulgaricus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 32
- 230000007815 allergy Effects 0.000 title claims abstract description 30
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 21
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 20
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title description 7
- 230000028327 secretion Effects 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 25
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 17
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 17
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 17
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 126
- 235000014655 lactic acid Nutrition 0.000 claims description 63
- 239000004310 lactic acid Substances 0.000 claims description 63
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 46
- 230000001580 bacterial effect Effects 0.000 claims description 36
- 241000894006 Bacteria Species 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 18
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 17
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 238000012827 research and development Methods 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 238000003501 co-culture Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 244000199866 Lactobacillus casei Species 0.000 description 7
- 235000013958 Lactobacillus casei Nutrition 0.000 description 7
- 229940017800 lactobacillus casei Drugs 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000024833 regulation of cytokine production Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW091119957A TWI277651B (en) | 2002-09-02 | 2002-09-02 | New use of some lactobacillus strains in treating allergy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004091491A true JP2004091491A (ja) | 2004-03-25 |
| JP2004091491A5 JP2004091491A5 (enExample) | 2005-05-26 |
Family
ID=32067572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003310760A Pending JP2004091491A (ja) | 2002-09-02 | 2003-09-02 | アレルギーを処置する際のいくつかのＬａｃｔｏｂａｃｉｌｌｕｓ株の新規使用 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2004091491A (enExample) |
| TW (1) | TWI277651B (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004096246A1 (ja) * | 2003-03-13 | 2004-11-11 | Kirin Beer Kabushiki Kaisha | 抗アレルギー用組成物 |
| WO2006093022A1 (ja) | 2005-03-03 | 2006-09-08 | Meiji Dairies Corporation | 免疫機能調整剤 |
| JP2006273783A (ja) * | 2005-03-30 | 2006-10-12 | Musashino Seiyaku Kk | 掻痒の予防及び／又は治療用組成物 |
| KR100745013B1 (ko) | 2006-01-25 | 2007-08-10 | 주식회사 알엔에이 | 알러지 질환 예방 및 치료를 위한 유산균 |
| EP1941892A3 (en) * | 2007-01-05 | 2009-08-19 | Promd Biotech Co., Ltd. | Anti-allergy lactic acid bacteria |
| TWI386163B (zh) * | 2007-01-05 | 2013-02-21 | Promd Biotech Co Ltd | 抗過敏之乳酸菌 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101075557B1 (ko) * | 2008-12-03 | 2011-10-20 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| KR101255050B1 (ko) * | 2009-07-14 | 2013-04-16 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| KR101486999B1 (ko) * | 2009-07-22 | 2015-01-28 | 씨제이제일제당 주식회사 | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| KR101178217B1 (ko) * | 2009-10-28 | 2012-09-07 | 씨제이제일제당 (주) | 신규한 락토바실러스 플란타룸 및 이를 포함하는 조성물 |
| TWI453281B (zh) * | 2012-03-28 | 2014-09-21 | New Bellus Entpr Co Ltd | 抗過敏之乳酸菌及其組合物 |
-
2002
- 2002-09-02 TW TW091119957A patent/TWI277651B/zh not_active IP Right Cessation
-
2003
- 2003-09-02 JP JP2003310760A patent/JP2004091491A/ja active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004096246A1 (ja) * | 2003-03-13 | 2004-11-11 | Kirin Beer Kabushiki Kaisha | 抗アレルギー用組成物 |
| WO2006093022A1 (ja) | 2005-03-03 | 2006-09-08 | Meiji Dairies Corporation | 免疫機能調整剤 |
| US9314041B2 (en) | 2005-03-03 | 2016-04-19 | Meiji Co., Ltd. | Immune function modulating agents |
| JP2006273783A (ja) * | 2005-03-30 | 2006-10-12 | Musashino Seiyaku Kk | 掻痒の予防及び／又は治療用組成物 |
| KR100745013B1 (ko) | 2006-01-25 | 2007-08-10 | 주식회사 알엔에이 | 알러지 질환 예방 및 치료를 위한 유산균 |
| EP1941892A3 (en) * | 2007-01-05 | 2009-08-19 | Promd Biotech Co., Ltd. | Anti-allergy lactic acid bacteria |
| TWI386163B (zh) * | 2007-01-05 | 2013-02-21 | Promd Biotech Co Ltd | 抗過敏之乳酸菌 |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI277651B (en) | 2007-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7121233B2 (ja) | ラクトバチルス・パラカゼイ株及びその使用 | |
| Marin et al. | Stimulation of cytokine production in clonal macrophage and T-cell models by Streptococcus thermophilus: comparison with Bifidobacterium sp. and Lactobacillus bulgaricus | |
| JP4942831B2 (ja) | 抗アレルギー用組成物 | |
| Gaudana et al. | Probiotic attributes of Lactobacillus strains isolated from food and of human origin | |
| US20040047849A1 (en) | Use of some lactobacillus strains in treating allergy | |
| JPH092959A (ja) | ＩｇＥ抗体産生抑制剤および抗アレルギー剤 | |
| CN102399718B (zh) | 副干酪乳酸杆菌株gmnl‑133、用于改善异位性皮肤炎或其它过敏疾病的组合物及其用途 | |
| EP2581461B1 (en) | Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases | |
| KR102106737B1 (ko) | 면역증강 활성을 가진 락토바실러스 퍼멘텀 BioE LF11 사균체를 포함하는 면역증강 조성물 | |
| JP2004091491A (ja) | アレルギーを処置する際のいくつかのＬａｃｔｏｂａｃｉｌｌｕｓ株の新規使用 | |
| KR20080081486A (ko) | 신규 유산균 균주 및 이를 포함하는 유산균 제제 | |
| CN100396771C (zh) | 新的微生物株类干酪乳杆菌gm-080及其治疗过敏相关疾病的用途 | |
| US20140348792A1 (en) | Methods to reduce polyposis and colorectal cancer | |
| TWI398259B (zh) | 副乾酪乳酸桿菌株ｇｍｎｌ－１３３用於改善異位性皮膚炎或其他過敏疾病之組合物及其用途 | |
| US7351572B2 (en) | Microorganism strain GM-090 of Lactobacillus fermentum and its use for stimulating IFN-γ secretion and/or treating allergy | |
| Cukrowska et al. | Impact of heat-inactivated Lactobacillus casei and Lactobacillus paracasei strains on cytokine responses in whole blood cell cultures of children with atopic dermatitis | |
| TWI509069B (zh) | 具有免疫調節及抗過敏作用的乳酸菌 | |
| US8753624B2 (en) | Composition and use of Lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases | |
| JP4847038B2 (ja) | ラクトバチルス・パラカゼイの新規微生物株ｇｍ−０８０及びアレルギー関連疾患を処置するためのその使用 | |
| Hyung et al. | Therapeutic effects of orally administered CJLP55 for atopic dermatitis via the regulation of immune response | |
| TW201106957A (en) | The new strain of Lactobacillus plantarum LP28 and its use in treating allergy | |
| JP2019077694A (ja) | 免疫疾患予防剤 | |
| CN1498627A (zh) | 乳酸杆菌菌株在治疗过敏中之新用途 | |
| Tsai et al. | Oral administration of multiple lactic acid bacteria strains suppressed allergic responses IgE in an ovalbumin-induced allergy BALB/c mouse model | |
| JP4823503B2 (ja) | Ｌａｃｔｏｂａｃｉｌｌｕｓｆｅｒｍｅｎｔｕｍの新規微生物株ＧＭ−０９０、およびＩＦＮ−γ分泌の刺激および／またはアレルギーの処置のためのその使用。 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040420 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071102 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080128 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080131 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080425 |